Clinical Trials Logo

Clinical Trial Summary

This study is designed as a combination of phase 1 (Part A) and phase 2 (Part B). The purpose of Part A was to determine the safety, tolerability, and pharmacokinetics in patients with total thyroidectomy or near total thyroidectomy of GX-30 and it has been completed. The Part B is currently recruiting and will investigate the efficacy and safety of GX-30 compared with THYROGEN®.


Clinical Trial Description

Recombinant human TSH was developed to provide TSH stimulation without withdrawal of thyroid hormone. Radioiodine ablation and diagnosis with rhTSH became the standard of care treatment for patients with differentiated thyroid cancer. Stably supplying rhTSH has been the unmet need for management and follow-up procedure for thyroid remnant. GX-30 is an investigational product, developed to provide inexpensive rhTSH to patients in order to ensure stable supply of rhTSH. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03276988
Study type Interventional
Source Genexine, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 7, 2017
Completion date January 20, 2020

See also
  Status Clinical Trial Phase
Completed NCT02089542 - Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery Phase 1/Phase 2
Recruiting NCT04012476 - Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy Phase 4
Completed NCT02167529 - Quality of Life After Thyroidectomy (ThyrQol) N/A
Recruiting NCT05216419 - Prevention of Postoperative Hypocalcemia of Oral Vitamin D Supplementation Before Total Thyroidectomy Phase 4
Recruiting NCT06383091 - Impact of Manual Therapy on Laryngeal Function Following Total Thyroidectomy N/A
Completed NCT04212533 - Preoperative Hypocalcaemia, a Comparative Clinical Trial N/A
Recruiting NCT06288750 - Protective Effect of Indocyanine Green Fluorescence Imaging Technology on Parathyroid Glands During Total Thyroidectomy N/A